cosmic-313: cabo nivo ipi in 1l advanced rcc of imdc intermediate or poor risk
Published 1 year ago • 244 plays • Length 4:01Download video MP4
Download video MP3
Similar videos
-
2:56
#esmo22 highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. rcc: cosmic-313
-
1:49
cosmic-313: cabozantinib with nivolumab and ipilimumab in untreated arcc
-
4:22
cabozantinib in combination w/ nivolumab and ipilimumab of imdc intermediate or poor risk signif...
-
2:53
cosmic-313 points to first-line triplet option for advanced rcc | toni choueiri
-
4:23
esmo22: cabozantinib in combination with nivo & ipi in previously untreated arcc of imdc interme...
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
9:09
nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced rcc
-
1:26
neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccrcc
-
1:20
promising results of cabozantinib plus nivolumab in non-clear cell rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
1:40
phase iii meteor trial: cabozantinib vs everolimus for advanced clear cell renal cell carcinoma
-
5:44
hcrn-gu16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced rcc
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
5:59
prosper rcc study of perioperative nivolumab for renal cell carcinoma - future trial
-
4:55
survival from ext follow-up of trial of nivolumab & ipilimumab for the 1st-line treatment of adv rcc
-
3:31
cabozantinib–nivolumab and ipilimumab combinations show potential for gu cancers | andrea apolo